349 related articles for article (PubMed ID: 19794038)
1. Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens.
Pfaller MA; Messer SA; Georgopapadakou N; Martell LA; Besterman JM; Diekema DJ
J Clin Microbiol; 2009 Dec; 47(12):3797-804. PubMed ID: 19794038
[TBL] [Abstract][Full Text] [Related]
2. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
Guinea J; Peláez T; Recio S; Torres-Narbona M; Bouza E
Antimicrob Agents Chemother; 2008 Apr; 52(4):1396-400. PubMed ID: 18212101
[TBL] [Abstract][Full Text] [Related]
3.
Sun Y; Tan L; Yao Z; Gao L; Yang J; Zeng T
Microbiol Spectr; 2022 Feb; 10(1):e0200721. PubMed ID: 35019705
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of a Hos2 deacetylase inhibitor, MGCD290, in combination with echinocandins against echinocandin-resistant Candida species.
Pfaller MA; Rhomberg PR; Messer SA; Castanheira M
Diagn Microbiol Infect Dis; 2015 Apr; 81(4):259-63. PubMed ID: 25600842
[TBL] [Abstract][Full Text] [Related]
5. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
6. In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.
Chen SC; Biswas C; Bartley R; Widmer F; Pantarat N; Obando D; Djordjevic JT; Ellis DH; Jolliffe KA; Sorrell TC
Antimicrob Agents Chemother; 2010 Aug; 54(8):3233-40. PubMed ID: 20530227
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of miltefosine as a single agent and in combination with voriconazole or posaconazole against uncommon filamentous fungal pathogens.
Biswas C; Sorrell TC; Djordjevic JT; Zuo X; Jolliffe KA; Chen SC
J Antimicrob Chemother; 2013 Dec; 68(12):2842-6. PubMed ID: 23861311
[TBL] [Abstract][Full Text] [Related]
8.
Gao L; Xia X; Gong X; Zhang H; Sun Y
Front Cell Infect Microbiol; 2024; 14():1296151. PubMed ID: 38304196
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of posaconazole and comparators versus opportunistic filamentous fungal pathogens globally collected during 8 years.
Pfaller MA; Carvalhaes CG; Messer SA; Rhomberg PR; Castanheira M
Diagn Microbiol Infect Dis; 2021 Nov; 101(3):115473. PubMed ID: 34352433
[TBL] [Abstract][Full Text] [Related]
10. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
Lass-Flörl C; Mayr A; Perkhofer S; Hinterberger G; Hausdorfer J; Speth C; Fille M
Antimicrob Agents Chemother; 2008 Oct; 52(10):3637-41. PubMed ID: 18694949
[TBL] [Abstract][Full Text] [Related]
11. [In vitro susceptibility of fungal and yeast clinical isolates to itraconazole and voriconazole].
Morera-López Y; Torres-Rodríguez JM; Jiménez-Cabello T
Rev Iberoam Micol; 2005 Jun; 22(2):105-9. PubMed ID: 16107169
[TBL] [Abstract][Full Text] [Related]
12. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
Pfaller MA; Messer SA; Hollis RJ; Jones RN;
Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
[TBL] [Abstract][Full Text] [Related]
13.
Pfaller MA; Huband MD; Flamm RK; Bien PA; Castanheira M
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182527
[TBL] [Abstract][Full Text] [Related]
14. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.
Espinel-Ingroff A
J Clin Microbiol; 2001 Mar; 39(3):954-8. PubMed ID: 11230410
[TBL] [Abstract][Full Text] [Related]
15. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Bijie H; Dzierzanowska D; Klimko NN; Letscher-Bru V; Lisalova M; Muehlethaler K; Rennison C; Zaidi M;
J Clin Microbiol; 2009 Jan; 47(1):117-23. PubMed ID: 19005141
[TBL] [Abstract][Full Text] [Related]
16. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
Fera MT; La Camera E; De Sarro A
Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
[TBL] [Abstract][Full Text] [Related]
17. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
Karabıçak N; Alem N
Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
[TBL] [Abstract][Full Text] [Related]
18. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M
Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029
[TBL] [Abstract][Full Text] [Related]
19. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
20. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
Jensen RH
Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
